Valiant OrganicsQ3 FY24

Valiant Organics Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹348.2P/E: 17.5Market Cap: ₹976 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 1

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

No

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 1
  • FY25 revenue expected in the range of INR 900-1000 crores, with conservative estimates due to current market conditions.
  • Growth of approximately 40% anticipated in FY25 driven by volume improvement in PAP and new Pharma Intermediates and chlorophenol products.
  • Incremental revenue of around INR 200 crores expected from PAP at full capacity (~600-700 tons/month targeted by year-end).
  • Pharma Intermediates expected to contribute approximately INR 70-80 crores, with launch of eight new products planned early FY25.
  • OAP products likely to add INR 20-30 crores.
  • Capacity expansions have increased overall production capabilities significantly since 2020, with about 2000 MT added annually excluding PAP.
  • Market prices are subdued largely due to China dumping and global slowdown, but demand turnaround and new product launches expected to drive volumes and revenue growth beyond FY25.
  • Target EBITDA margin post expansion aimed upward of 20% by FY26 with innovation and product additions.

See what Valiant Organics management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • As of the Q3 FY24 earnings call in February 2024, Valiant Organics Limited has not indicated any immediate large-scale capital expenditure or fundraising plans through debt or equity for FY25.
  • The company mentioned standard maintenance CapEx of around INR 30-40 crores for FY25 but no major new projects yet; decisions on significant CapEx might be made in the second half of the current year.
  • Regarding term loan repayments, the company expects an outflow of about INR 40-50 crores in FY25 as two loans will retire (one in September, the other in February).
  • No explicit mention was made about raising new debt or equity capital during the call.
  • The company seems to be focusing on operational cash flows and repayments rather than raising fresh funds in the near term.

See what Valiant Organics management said on order book — free account, 30 seconds.

Capex plans

No
  • For FY25, Valiant Organics does not plan any large or significant CapEx, only standard maintenance CapEx of around INR 30-40 crores.
  • Any major CapEx decisions will be considered based on how the current year unfolds, potentially planned in the second half of the year for subsequent years.
  • No immediate major capital investment is planned until market conditions stabilize, especially given the current pricing pressures.
  • The company is focusing on scaling new products (like Pharma Intermediates, chlorophenol) rather than heavy CapEx projects.
  • Newer products in chlorophenol are expected to add to the product portfolio starting Q1 of the next fiscal year.
  • Two term loans are scheduled for retirement in FY25 (one in September, one in February), indicating some debt repayment outflows but no new large debt-financed investments mentioned.

Track Valiant Organics — get its next earnings analysis in your feed

How does Valiant Organics rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisValiant Organics
Rev 1Mar 1

How does Valiant Organics rank in Chemicals & Petrochemicals?

Compare Valiant Organics against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →